Heart Failure Patients With Ejection Fraction Improvement Rarely Withdrawn From Meds
By Lori Solomon HealthDay Reporter
.jpg?width=1200)
WEDNESDAY, March 26, 2025 -- In patients with heart failure with improved ejection fraction (EF), pharmacological therapy is rarely withdrawn, according to a study published online March 17 in Circulation.
Christian Basile, M.D., from the Karolinska Institutet in Stockholm, and colleagues assessed rates, patient profiles, and associations with morbidity/mortality of renin-angiotensin inhibitors (RASi), angiotensin receptor-neprilysin inhibitors (ARNi), beta-blockers (BBL), and mineralocorticoid receptor antagonist (MRA) withdrawal in patients with heart failure with improved EF. The analysis included 8,728 patients with heart failure with improved EF (first recorded EF <40 percent and a later EF ≥40 percent).
The researchers found that the withdrawal rates at the time of the improved EF registration were 4.4 percent for RASi/ARNi, 3.3 percent for BBL, and 17.2 percent for MRA. Lower use of other heart failure medications, higher EF at the later EF registration, and a longer time between the two EF assessments were predictors of withdrawal. Withdrawal was independently associated with a higher risk for cardiovascular mortality/hospitalization at one year for heart failure by 38 percent for RASi/ARNi and 36 percent for MRA after weighting, but there was no association for BBL. There was an association with a higher risk for the primary outcome in the subgroup of patients withdrawn from BBL with an improved EF of 40 to 49 percent versus ≥50 percent.
"These results are hypothesis-generating and highlight the need for randomized controlled trials testing BBL withdrawal in patients with heart failure with improved EF," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Seniors With RSV-Linked Hospitalization Have Increased Cardiovascular Outcomes
THURSDAY, July 24, 2025 -- In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events...
Wildfire Smoke Exposure Increases Risk for Heart Failure
TUESDAY, July 8, 2025 -- Wildfire smoke exposure over time may increase the risk for heart failure, according to a study published in the July issue of the Journal of the...
A-Fib Catheter Ablation Cuts Risk for Ischemic Stroke After 30 Days, Mortality, Heart Failure Hospitalization
MONDAY, July 7, 2025 -- For patients with atrial fibrillation, catheter ablation reduces the risks for ischemic stroke at more than 30 days, mortality, and heart failure...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.